{
    "nctId": "NCT00637871",
    "briefTitle": "Casodex - Nolvadex Combination",
    "officialTitle": "Randomised, Double-blind, Placebo Controlled, Parallel-group, Multicentre Phase II Study to Assess Dose Response Relationship of Nolvadex (Oral Tablet) in Prophylactic Treatment of Gynaecomastia and Breast Pain Associated With CASODEX 150 mg (Oral Tablet), and to Assess the Tumour Control\u2026..",
    "overallStatus": "COMPLETED",
    "conditions": "Gynaecomastia, Prostate Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": "N/A",
    "primaryOutcomeMeasure": "N/A",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with adenocarcinoma of the prostate gland but with no evidence of distant metastasis. The stage of disease should be T1-T4, any N, M0 confirmed histologically or cytologically\n* Subjects in need of immediate hormonal therapy.\n* PSA equal or above 4 ng/ml\n\nExclusion Criteria:\n\n* Presence of gynaecomastia and/or breast pain at screening visit\n* Any previous endocrine therapy for prostate cancer other than neoadjuvant LHRH therapy prior to primary therapy of curative intent.\n* Current use, or within the previous 6 months, of any medication known to have a high risk of causing gynaecomastia .\n* Previous mastectomy or radiation to chest wall",
    "sex": "MALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}